Cortisol and depression in pre-diagnosed and early stage Huntington's disease

Psychoneuroendocrinology

Volumn 38, Issue 11, 2013, Pages 2439-2447

  Shirbin, Christopher A ^a   Chua, Phyllis ^a,b,c   Churchyard, Andrew ^a,b,d   Lowndes, Georgia ^a   Hannan, Anthony J ^c   Pang, Terence Y ^c   Chiu, Edmond ^a,b,c   Stout, Julie C ^a  

^a MONASH UNIVERSITY   (Australia)

^b Academic Unit Old Age Psychiatry   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Huntington's Disease Service   (Australia)

Author keywords

Cortisol; Depression; Huntington's disease; Hypothalamic pituitary adrenal axis; Saliva; Stress

Indexed keywords

HYDROCORTISONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUNTINGTON CHOREA; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SALIVA LEVEL; SELF REPORT; SEX DIFFERENCE; SLEEP QUALITY;

CORTISOL; DEPRESSION; HUNTINGTON'S DISEASE; HYPOTHALAMIC-PITUITARY-ADRENAL AXIS; SALIVA; STRESS;

ADULT; AGED; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; DEPRESSION; HUMANS; HUNTINGTON DISEASE; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; SALIVA;

EID: 84886091618     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.10.020     Document Type: Article

References (52)

1. Almqvist E.W., Brinkman R.R., Wiggins S., Hayden M.R. Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. Clin. Genet. 2003, 64:300-309.
2. Aylward E.H., Sparks B.F., Field K.M., Yallapragada V., Shpritz B.D., Rosenblatt A., Brandt J., Gourley L.M., Liang K., Zhou H., Margolis R.L., Ross C.A. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004, 63:66-72.
3. Aziz N.A., Pijl H., Frolich M., Van der Graaf A.W.M., Roelfsema F., Roos R.A.C. Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. J. Clin. Endocrinol. Metab. 2009, 94:1223-1228.
4. Bhagwagar Z., Hafizi S., Cowen P.J. Increased salivary cortisol after waking in depression. Psychopharmacology 2005, 182:54-57.
5. Björkqvist M., Petersén A., Bacos K., Isaacs J., Norlén P., Gil J., Popovic N., Sundler F., Bates G.P., Tabrizi S.J., Brundin P., Mulder H. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:1713-1721.
6. Bremmer M.A., Deeg D.J., Beekman A.T., Penninx B.W., Lips P., Hoogendijk W.J. Major depression in late life is associated with both hypo- and hypercortisolemia. Biol. Psychiatry 2007, 62:479-486.
7. Bremner J.D., Vythilingam M., Vermetten E., Adil J., Khan S., Nazeer A., Afzal N., McGlashan T., Elzinga B., Anderson G.M., Heninger G., Southwick S.M., Charney D.S. Cortisol response to a cognitive stress challenge in posttraumatic stress disorder (PTSD) related to childhood abuse. Psychoneuroendocrinology 2003, 28:733-750.
8. Buysse D.J., Reynolds 3rd C.F., Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28:193-213.
9. Cohen S., Kamarck T., Mermelstein R. A global measure of perceived stress. J. Health Soc. Behav. 1983, 24:385-396.
10. Craufurd D., Thompson J.C., Snowden J.S. Behavioral changes in Huntington Disease. Neuropsychiatry Neuropsychol. Behav. Neurol. 2001, 14:219-226.
11. Dalrymple A., Wild E.J., Joubert R., Sathasivam K., Björkqvist M., Petersén Å., Jackson G.S., Isaacs J.D., Kristiansen M., Bates G.P., Leavitt B.R., Keir G., Ward M., Tabrizi S.J. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 2007, 6:2833-2840.
12. Downing N., Smith M.M., Beglinger L.J., Mills J., Duff K., Rowe K.C., Epping E., Paulsen J.S. Perceived stress in prodromal Huntington disease. Psychol. Health 2011, 1:1-14.
13. Duff K., Paulsen J.S., Beglinger L.J., Langbehn D.R., Stout J.C. The Predict-HD investigators of the Huntington study group. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol. Psychiatry 2007, 62:1341-1346.
14. Gil J.M., Mohapel P., Araújo I.M., Popovic N., Li J.Y., Brundin P., Petersén A. Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice. Neurobiol. Dis. 2005, 20:744-751.
15. Gold P.W., Goodwin F.K., Chrousos G.P. Clinical and biochemical manifestations of depression: relation to the neurobiology of stress. N. Engl. J. Med. 1988, 319(Part 2 of 2 parts):413-420.
16. Heim C., Newport D.J., Heit S., Graham Y.P., Wilcox M., Bonsall R., Miller A.H., Nemeroff C.B. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 2000, 284:592-597.
17. Heuser I.J.E., Chase T.N., Maral Mouradian M. The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease. Biol. Psychiatry 1991, 30:943-952.
18. Hinkelmann K., Moritz S., Botzenhardt J., Riedesel K., Wiedemann K., Kellner M., Otte C. Cognitive impairment in major depression: association with salivary cortisol. Biol. Psychiatry 2009, 66:879-885.
19. Huntington Study Group Unified Huntington's disease rating scale: reliability and consistency. Mov. Disord. 1996, 11:136-142.
20. Julien C.L., Thompson J.C., Wild S., Yardumian P., Snowden J.S., Turner G., Craufurd D. Psychiatric disorders in preclinical Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2007, 78:939-943.
21. Kassubek J., Juengling F.D., Kioschies T., Henkel K., Karitzky J., Kramer B., Ecker D., Andrich J., Saft C., Kraus P., Aschoff A.J., Ludolph A.C., Landwehrmeyer G.B. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J. Neurol. Neurosurg. Psychiatry 2004, 75:213-220.
22. Kurlan R., Caine E., Rubin A., Nemeroff C.B., Bissette G., Zaczek R., Coyle J., Spielman F.J., Irvine C., Shoulson I. Cerebrospinal fluid correlates of depression in Huntington's disease. Arch. Neurol. 1988, 45:881-883.
23. Lazic S.E., Grote H., Armstrong R.J., Blakemore C., Hannan A.J., Van Dellen A., Barker R.A. Decreased hippocampal cell proliferation in R6/1 Huntington's mice. Neuroreport 2004, 15:811-813.
24. Leblhuber F., Peichl M., Neubauer C., Reisecker F., Steinparz F.X., Windhager E., Maschek W. Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea. J. Neurol. Sci. 1995, 132:76-79.
25. Nikisch G., Mathé A.A., Czernik A., Thiele J., Bohner J., Eap C.B., Agren H., Baumann P. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology 2005, 181:751-760.
26. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008, 31:464-468.
27. Paulsen J.S., Nehl C., Hoth K.F., Kanz J.E., Benjamin M., Conybeare R., McDowell B., Turner B. Depression and stages of Huntington's disease. J. Neuropsychiatry Clin. Neurosci. 2005, 17:496-502.
28. Penney J.B., Vonsattel J.P., MacDonald M.E., Gusella J.F., Myers R.H. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol. 1997, 41:689-692.
29. Penninx B.W., Beekman A.T., Bandinelli S., Corsi A.M., Bremmer M., Hoogendijk W.J., Guralnik J.M., Ferrucci L. Late-life depressive symptoms are associated with both hyperactivity and hypoactivity of the hypothalamo-pituitary-adrenal axis. Am. J. Geriatr. Psychiatry 2007, 15:522-529.
30. Petersén A., Björkqvist M. Hypothalamic-endocrine aspects in Huntington's disease [Review]. Eur. J. Neurosci. 2006, 24:961-967.
31. Poll E.M., Kreitschmann-Andermahr I., Langejuergen Y., Stanzel S., Gilsbach J.M., Gressner A., Yagmur E. Saliva collection method affects predictability of serum cortisol. Clin. Chim. Acta 2007, 382:15-19.
32. Pruessner J.C., Wolf O.T., Hellhammer D.H., Buske-Kirschbaum A., Von Auer K., Jobst S., Kaspers F., Kirschbaum C. Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity. Life Sci. 1997, 61:2539-2549.
33. Raison C.L., Miller A.H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 2003, 160:1554-1565.
34. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., Caplan K., Marek K., Seidman L.J., Makris N., Jenkins B.G., Goldstein J.M. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003, 60:1615-1620.
35. Rush A.J., Gullion C.M., Basco M.R., Jarrett R.B., Trivedi M.H. The inventory of depressive symptomatology (IDS): psychometric properties. Psychol. Med. 1996, 26:477-486.
36. Sachar E.J., Hellman L., Roffwarg H.P., Halpern F.S., Fukushima D.K., Gallagher T.F. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch. Gen. Psychiatry 1973, 28:19-24.
37. Saleh N., Moutereau S., Durr A., Krystkowiak P., Azulay J.-P., Tranchant C., Broussolle E., Morin F., Bachoud-Levi A.-C., Maison P. Neuroendocrine disturbances in Huntington's disease. PLoS ONE 2009, 4:e4962.
38. Scharnholz B., Weber-Hamann B., Lederbogen F., Schilling C., Gilles M., Onken V., Frankhauser P., Kopf D., Deuschle M. Antidepressant treatment with mirtazapine, but not venlafaxine, lowers cortisol concentrations in saliva: a randomised open trial. Psychiatry Res. 2010, 177:109-113.
39. Shirtcliff E.A., Granger D.A., Schwartz E., Curran M.J. Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results. Psychoneuroendocrinology 2001, 26:165-173.
40. Shiwach R. Psychopathology in Huntington's disease patients. Acta Psychiatr. Scand. 1994, 90:241-246.
41. Simpson J.M., Gil-Mohapel J., Pouladi M.A., Ghilan M., Xie Y., Hayden M.R., Christie B.R. Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiol. Dis. 2011, 41:249-260.
42. Soneson C., Fontes M., Zhou Y., Denisov V., Paulsen J.S., Kirik D., Petersén Å. The Huntington Study Group PREDICT-HD investigators. Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol. Dis. 2010, 40:531-543.
43. Spargo E., Everall I.P., Lantos P.L. Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J. Neurol. Neurosurg. Psychiatry 1993, 56:487-491.
44. Spitzer R.L., Williams J.B., Kroenke K., Linzer M., deGruy F.V., Hahn S.R., Brody D., Johnson J.G. Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. JAMA 1994, 272:1749-1756.
45. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
46. Van Cauter E., Leproult R., Kupfer D.J. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J. Clin. Endocrinol. Metab. 1996, 81:2468-2473.
47. van Duijn E., Kingma E.M., Timman R., Zitman F.G., Tibben A., Roos R.A., Van der Mast R.C. Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington's disease compared with mutation-negative first-degree relatives. J. Clin. Psychiatry 2008, 69:1804-1810.
48. Duijn E.V., Selis M.A., Giltay E.J., Zitman F.G., Roos R.A., Van Pelt H., Van der Mast R.C. Hypothalamic-pituitary-adrenal axis functioning in Huntington's disease mutation carriers compared with mutation-negative first-degree controls. Brain Res. Bull. 2010, 83:232-237.
49. Vogeser M., Durner J., Seliger E., Auernhammer C. Measurement of late-night salivary cortisol with an automated immunoassay system. Clin. Chem. Lab. Med. 2006, 44:1441-1445.
50. Wardenaar K.J., Vreeburg S.A., Van Veen T., Giltay E.J., Veen G., Penninx B.W., Zitman F.G. Dimensions of depression and anxiety and the hypothalamo-pituitary-adrenal axis. Biol. Psychiatry 2011, 69:366-373.
51. Watson S., Gallagher P., Del-Estal D., Hearn A., Ferrier I.N., Young A.H. Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. Psychol. Med. 2002, 32:1021-1028.
52. Weitzman E.D., Fukushima D., Nogeire C., Roffwarg H., Gallagher T.F., Hellman L. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J. Clin. Endocrinol. Metab. 1971, 33:14-22.